iRadimed (NASDAQ:IRMD) Updates FY 2026 Earnings Guidance

iRadimed (NASDAQ:IRMD) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 2.090-2.240 for the period, compared to the consensus EPS estimate of 1.960. The company issued revenue guidance of $91.0 million-$96.0 million, compared to the consensus revenue estimate of $91.2 million. iRadimed also updated its Q3 2026 guidance to 0.540-0.590 EPS.

Wall Street Analyst Weigh In

A number of equities analysts have commented on IRMD shares. Freedom Capital raised shares of iRadimed to a “strong-buy” rating in a research report on Thursday, April 2nd. Weiss Ratings cut shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, May 20th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat, iRadimed currently has a consensus rating of “Buy” and an average target price of $120.00.

iRadimed Trading Up 1.0%

NASDAQ IRMD opened at $95.21 on Friday. The company has a market cap of $1.22 billion, a price-to-earnings ratio of 52.03 and a beta of 0.90. The company has a 50 day moving average of $94.56 and a 200-day moving average of $95.73. iRadimed has a 1-year low of $57.83 and a 1-year high of $107.90.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.42 by $0.04. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, equities research analysts forecast that iRadimed will post 1.52 earnings per share for the current year.

Insider Buying and Selling at iRadimed

In related news, CEO Roger E. Susi sold 2,500 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.60, for a total transaction of $226,500.00. Following the sale, the chief executive officer owned 2,162,500 shares in the company, valued at approximately $195,922,500. This trade represents a 0.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 21,250 shares of company stock worth $1,836,403. Corporate insiders own 34.60% of the company’s stock.

Hedge Funds Weigh In On iRadimed

Several institutional investors and hedge funds have recently added to or reduced their stakes in IRMD. Quarry LP acquired a new position in shares of iRadimed during the third quarter worth $40,000. Tower Research Capital LLC TRC increased its holdings in iRadimed by 191.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 495 shares in the last quarter. Virtus Advisers LLC bought a new position in iRadimed in the third quarter valued at about $117,000. Aquatic Capital Management LLC boosted its stake in shares of iRadimed by 210,400.0% during the third quarter. Aquatic Capital Management LLC now owns 2,105 shares of the medical equipment provider’s stock valued at $150,000 after purchasing an additional 2,104 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in shares of iRadimed during the third quarter worth about $164,000. Institutional investors own 92.34% of the company’s stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.